A comparative study of efficacy and safety of febuxostat and allopurinol in pyrazinamide-induced hyperuricemic tubercular patients
Open Access
- 1 January 2016
- journal article
- research article
- Published by Medknow in Indian Journal of Pharmacology
- Vol. 48 (5) , 522-525
Abstract
Objectives: To compare the efficacy and safety of febuxostat and allopurinol in pyrazinamide (PZA)-induced hyperuricemia in patients taking antitubercular therapy (ATT). Methods: This randomized controlled study was conducted at a tertiary care teaching institute of Rajasthan in all the sputum-positive tubercular patients aged between 18 and 65 years of either sex. Serum uric acid level was monitored at 0 th , 2 nd , 4 th , 6 th , and 8 th week of ATT. Patients whose uric acid level was found to be increased at 2 nd week were finally recruited in the study. Ninety patients who developed hyperuricemia due to ATT were divided randomly into three groups (Group A - febuxostat, Group B - allopurinol, and Group C - control) of thirty patients each. Mean serum uric acid levels were calculated at all the weeks in all the groups, and serum uric acid levels were compared by applying student's t-test and ANOVA. Results: Mean serum uric acid level decreased from 10.698 mg/dl (at 2 nd week) to 7.846 mg/dl (at 8 th week) in Group A and from 11.34 mg/dl (at 2 nd week) to 7.280 mg/dl (at 8 th week) in Group B. Numbers of adverse events encountered across both the treatment groups were same with both the drugs. Conclusion: Allopurinol and febuxostat were equally efficacious in lowering PZA induced raised serum uric acid level in tubercular patients, and it was possible to continue ATT without withdrawing PZA.Keywords
This publication has 14 references indexed in Scilit:
- FebuxostatNature Reviews Drug Discovery, 2009
- Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety studyRheumatology, 2008
- Emerging therapies in the long‐term management of hyperuricaemia and goutInternal Medicine Journal, 2007
- Therapeutic Effects of Xanthine Oxidase Inhibitors: Renaissance Half a Century after the Discovery of AllopurinolPharmacological Reviews, 2006
- Febuxostat Compared with Allopurinol in Patients with Hyperuricemia and GoutNew England Journal of Medicine, 2005
- Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: A twenty‐eight–day, multicenter, phase II, randomized, double‐blind, placebo‐controlled, dose‐response clinical trial examining safety and efficacy in patients with goutArthritis & Rheumatism, 2005
- Allopurinol Hypersensitivity Syndrome: A ReviewAnnals of Pharmacotherapy, 1993
- The allopurinol hypersensitivity syndrome. Unnecessary morbidity and mortalityArthritis & Rheumatism, 1986
- Severe allopurinol toxicityThe American Journal of Medicine, 1984
- Renal function in goutThe American Journal of Medicine, 1969